ATCC Announces Award from Leidos Biomedical Research for the Production and Distribution of Next-Generation Cancer Models
Retrieved on:
Thursday, January 6, 2022
Oncology, Health, General Health, Research, Science, Pharmaceutical, Biotechnology, Plantar fibromatosis, 3D, Drug discovery, Doctor of Philosophy, Catalog, NCI, Research, CCG, Environment, Cancer, Leidos, Neck, Organoid, Head, Science, Laboratory, National Cancer Institute, History, Disease, Frederick National Laboratory for Cancer Research, CEO, HCMI, Health, Master chief petty officer, Culture, Senior, Lymphoma, 2D, Solution, Industry, Public health, Center, Neuroblastoma, Collection, Medical imaging, Pharmaceutical industry, ATCC
ATCC , the worlds premier biological materials management and standards organization, today announced that it has been awarded a contract with Leidos Biomedical Research, Inc. (Leidos Biomed), current operator of the Frederick National Laboratory for Cancer Research, for the continued production, characterization and distribution of next-generation cancer models (NGCM).
Key Points:
- ATCC , the worlds premier biological materials management and standards organization, today announced that it has been awarded a contract with Leidos Biomedical Research, Inc. (Leidos Biomed), current operator of the Frederick National Laboratory for Cancer Research, for the continued production, characterization and distribution of next-generation cancer models (NGCM).
- ATCC is at the core of enabling breakthroughs in cancer research by collaborating with HCMI to provide well-characterized 2D and 3D models for R&D studies, said James Clinton, Lead Scientist at ATCC.
- We look forward to supporting HCMIs efforts to prioritize the development of solutions to advance cancer research worldwide.
- ATCC is a non-profit organization with headquarters in Manassas, Virginia, and a research and development innovation center in Gaithersburg, Maryland.